Strong Generics-led finish to 2023
22/02/24 -"Hikma’s H2 23 results exceeded the street’s expectations, with Generics being the lead performer. Even the 2024 guidance was largely in line with the consensus estimates. The results were cheered by ..."
Pages
55
Language
English
Published on
22/02/24
You may also be interested by these reports :
17/09/26
Although our estimates have increased by double digits, the target price has been raised at a lower rate due to Ipsen’s near- and mid-term risks. ...
15/09/26
At a time when Novartis and AstraZeneca nurse a run of late-stage R&D setbacks, GSK’s recent clinical trial successes for oncology candidates, ...
14/09/26
Since its July 2022 listing, Haleon (BUY; UK) has delivered a total return of just under 20%. Unexciting, but not for want of progress. Assembled ...
11/09/26
The recent R&D setbacks in cardiovascular and neuroscience areas have prompted us to revise our target price downwards. In the process, we have also ...